Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

24.43 +1.78 (+7.86%)
Streaming Delayed Price Updated: 3:06 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 289,464
Open 22.61
Bid (Size) 24.36 (2)
Ask (Size) 24.47 (1)
Prev. Close 22.65
Today's Range 22.49 - 24.65
52wk Range 12.21 - 41.31
Shares Outstanding 27,433,359
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May
Via Benzinga

Performance

YTD
+82.9%
+82.9%
1 Month
+11.8%
+11.8%
3 Month
+32.8%
+32.8%
6 Month
+84.5%
+84.5%
1 Year
-0.7%
-0.7%

More News

Read More
This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering
Via Stocktwits
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
From AnaptysBio, Inc.
Via GlobeNewswire
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock
Via Benzinga
Where AnaptysBio Stands With Analysts
Via Benzinga
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
Forecasting The Future: 6 Analyst Projections For AnaptysBio
Via Benzinga
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Gains 1%; US Composite PMI Surges In March
Via Benzinga
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday
Via Benzinga
Anaptys Announces Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Anaptys Announces Participation in March Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
Via Investor's Business Daily
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
From AnaptysBio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
From AnaptysBio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is AnaptysBio, Inc. - Common Stock publicly traded?
Yes, AnaptysBio, Inc. - Common Stock is publicly traded.
What exchange does AnaptysBio, Inc. - Common Stock trade on?
AnaptysBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for AnaptysBio, Inc. - Common Stock?
The ticker symbol for AnaptysBio, Inc. - Common Stock is ANAB on the Nasdaq Stock Market
What is the current price of AnaptysBio, Inc. - Common Stock?
The current price of AnaptysBio, Inc. - Common Stock is 24.43
When was AnaptysBio, Inc. - Common Stock last traded?
The last trade of AnaptysBio, Inc. - Common Stock was at 07/02/25 03:06 PM ET
What is the market capitalization of AnaptysBio, Inc. - Common Stock?
The market capitalization of AnaptysBio, Inc. - Common Stock is 670.20M
How many shares of AnaptysBio, Inc. - Common Stock are outstanding?
AnaptysBio, Inc. - Common Stock has 670M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.